Embecta, which made its public debut Friday on the Nasdaq, encompasses BD’s century-old diabetes division—responsible for producing insulin syringes, pens and more—that brought in around $1.2 billion ...

Becton, Dickinson and Co.’s board of directors approved the company’s diabetes spinoff, and set a date of April 1 for the move. The announcement of Embecta Corp.’s approval came Feb. 1, along with a ...

Carrying over the “bect” in its logo as a nod to Becton, Dickinson and Company, embecta will maintain international manufacturing sites that previously produced around 8 billion injection devices ...

FRANKLIN LAKES, N.J., Feb. 1, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of directors has approved the ...

Under the transaction terms, BD shareholders received one share of Embecta stock for every five shares of BD that they held as of March 22. The Embecta spinoff severs all financial ties to BD, which ...

It’s official: Embecta Corp. is now one of the largest pure-play diabetes management companies worldwide. On April 1, Franklin Lakes-based BD announced it completed the spinoff of its former Diabetes ...

Over 2,000 employees globally serving more than 100 countries. FRANKLIN LAKES, N.J., April 01, 2022 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (NASDAQ: EMBC) and its employees around the world ...

Nearly a year ago, Becton Dickinson and Co. said it was spinning off its diabetes care business into a publicly-traded company. The end result was Embecta – a new company with a rich history that ...

Embecta (EMBC) is a medical devices company focused on diabetes management. It offers a variety of pen needles, syringes, and other assorted tools to help diabetic patients. A much larger company, ...